Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel？, Montanide ISA 720 or AS02 英文参考文献.docVIP

下载本文档

7
0
约5.68万字
约 12页
2017-05-13 发布于上海
举报
版权申诉

Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel？, Montanide ISA 720 or AS02 英文参考文献.doc

1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
7、VIP文档为合作方或网友上传，每下载1次，网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档

Safety and Immunogenicity of a Recombinant Plasmodium falciparum AMA1 Malaria Vaccine Adjuvanted with Alhydrogel？, Montanide ISA 720 or AS02 英文参考文献

SafetyandImmunogenicityofaRecombinant PlasmodiumfalciparumAMA1MalariaVaccine AdjuvantedwithAlhydrogelTM,MontanideISA720or AS02 MetaRoestenberg1*,EdRemarque2,ErikdeJonge1,RobHermsen1,HildurBlythman3,OdileLeroy3, EgeruanImoukhuede3,SorenJepsen3,OpokuaOfori-Anyinam4,BartFaber2,ClemensH.M.Kocken2, MirandaArnold2,VanessaWalraven2,KarinaTeelen1,WillRoeffen1,QuirijndeMast1,W.RipleyBallou4¤, JoeCohen4,MarieClaudeDubois4,Ste′phaneAscarateil5,AndrevanderVen1,AlanThomas2 ,Robert Sauerwein1 1RadboudUniversityNijmegenMedicalCentre,Nijmegen,TheNetherlands,2BiomedicalPrimateResearchCentre,Rijswijk,TheNetherlands,3EuropeanMalariaVaccine Initiative,Copenhagen,Denmark,4GlaxoSmithKlineBiologicals,Rixensart,Belgium,5SEPPIC,Paris,France Abstract Background: Plasmodium falciparum Apical Membrane Antigen 1 (PfAMA1) is a candidate vaccine antigen expressed by merozoitesandsporozoites.Itplaysakeyroleinredbloodcellandhepatocyteinvasionthatcanbeblockedbyantibodies. Methodology/Principal Findings: We assessed the safety and immunogenicity of recombinant PfAMA1 in a dose- escalating,phaseIatrial.PfAMA1FVOstrain,producedinPichiapastoris,wasreconstitutedat10mgand50mgdoseswith TM threedifferentadjuvants,Alhydrogel ,MontanideISA720andAS02AdjuvantSystem.Sixrandomised groupsofhealthy male volunteers, 8–10 volunteers each, were scheduled to receive three immunisations at 4-week intervals. Safety and immunogenicitydatawerecollectedoveroneyear.Transientpainwasthepredominantinjectionsitereaction(80–100%). IndurationoccurredintheMontanide50mggroup,resultinginasterileabscessintwovolunteers.Systemicadverseevents occurredmainlyintheAS02groupslastingfor1–2days.Erythemawasobservedin22%ofMontanideand59%ofAS02 groupvolunteers.Aftertheseconddose,sixvolunteersintheAS02groupandoneintheMontanidegroupwhoreported grade3erythema(.50mm)werewithdrawnastheymetthestoppingcriteria.Alladverseeventsresolved.Therewereno vaccine-relatedseriousadverseevents.HumoralresponseswerehighestintheAS02groups.Antibodiesshowedacti